LR Health & Beauty SE, a leading European social commerce company for nutritional supplements and beauty products, has published its final annual report for 2025, confirming the preliminary sales and earnings figures. The company reported group sales of EUR 277.1 million for the full year, down from EUR 289.2 million in 2024. Reported EBITDA fell to EUR 16.5 million from EUR 27.3 million, impacted by one-off effects from the reorganization of the financing structure. Normalized EBITDA for the year was EUR 22.5 million, compared with EUR 32.6 million in the previous year.
The announcement is significant as it underscores the company's strategic pivot towards long-term sustainability. CEO Jorg Korfer emphasized that 2026 is a transitional year, with the newly established financing structure providing the momentum to consistently pursue initiatives in production, logistics, and sales. "We are committed to working closely with our partners and are continuing to expand these relationships internationally," he stated.
A key strategic pillar is expanding in-house production. LR is investing over EUR 2 million in a new, high-performance production line at its Ahlen site, centralizing the manufacture of its 5in1 product category, which includes the popular LR 5in1 Beauty Elixir and LR 5in1 Men's Shot. The new facility is designed to have an annual capacity of up to 40 million units and will also enable further product innovations in modern nutritional supplement concepts.
This investment is crucial for the company's future competitiveness, allowing for greater control over production quality and efficiency. By bringing production in-house, LR aims to reduce reliance on external manufacturers and streamline its supply chain, which is expected to improve margins and support innovation.
The full 2025 Annual Report is now available on the company's website at https://ir.lrworld.com. This transparency is part of LR's commitment to keeping stakeholders informed about its financial health and strategic direction.
The company's focus on social commerce and direct selling remains a differentiator in the market. With operations in 32 countries, LR leverages digital tools like its "LR neo" dashboard to support its international partnership. This business model appeals to individuals seeking flexibility and financial independence, aligning with changing work environments.
The implications of this report are far-reaching. For investors, the confirmed figures provide a clear picture of the company's current financial standing and its potential for recovery. For the industry, LR's investment in production capacity signals confidence in the growing demand for nutritional supplements. The company's ability to innovate and adapt will be closely watched as it navigates this transitional year and strives for sustainable growth.
In summary, LR Health & Beauty's final annual report not only validates its previous guidance but also highlights strategic investments aimed at long-term value creation. As the company executes its initiatives, stakeholders will be looking for signs of improvement in the coming quarters.
